Dr. Robin L. Williams, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
2450 Riverside Ave, Department Of Pediatrics
Minneapolis, MN 55454
At a glance
- Medical school
- University of Iowa, Rj & L Carver College of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of Iowa, Rj & L Carver College of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
MN license 58496
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Fairview Express Care (1,911 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $13,500 in research payments for these studies, mostly to the institutions running them.
- Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
Daiichi Sankyo Inc. · Active, not recruiting · NCT03793478 - Phase 12 study to evaluate palbociclib ibrance in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory solid tumors
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.